Skip to Content


In the US, Ruxolitinib (ruxolitinib systemic) is a member of the drug class multikinase inhibitors and is used to treat Myelofibrosis, Myeloproliferative Disorders and Polycythemia Vera.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories


Antineoplastic agent

Chemical Name

(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile (WHO)

Foreign Names

  • Ruxolitinibum (Latin)
  • Ruxolitinib (German)
  • Ruxolitinib (French)
  • Ruxolitinib (Spanish)

Generic Names

  • Ruxolitinib (OS: USAN, BAN)
  • INC-424 (IS)
  • INCB 018424 (IS)
  • UNII-82S8X8XX8H (IS)
  • Ruxolitinib Phosphate (OS: USAN, JAN, BANM)
  • INCB018424 salt (IS)
  • UNII-436LRU32H5 (IS)

Brand Names

  • Jakavi
    Novartis, Bosnia & Herzegowina; Novartis, Finland; Novartis, Hungary; Novartis, Lithuania; Novartis, Latvia; Novartis, Norway; Novartis, Poland; Novartis, Slovakia; Novartis Farma, Italy; Orifarm, Norway
  • Jakafi
    Incyte, United States
  • Jakavi
    Novartis, Belgium; Novartis, Chile; Novartis, Denmark; Novartis, France; Novartis, Hong Kong; Novartis, Croatia (Hrvatska); Novartis, Ireland; Novartis, Israel; Novartis, Iceland; Novartis, South Korea; Novartis, Sweden; Novartis, Thailand; Novartis Europharm, Austria; Novartis Europharm, Slovenia; Novartis Farmaceutica, Spain; Novartis Pharma, Switzerland; Novartis Pharma, Germany; Novartis Pharma, Russian Federation; Novartis Pharmaceuticals, Canada; Novartis Pharmaceuticals UK, United Kingdom


BANBritish Approved Name
BANMBritish Approved Name (Modified)
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.